Reference number : GC-2017-Q4-01223, amendment number : , agreement type : G, recipient legal name : McMillen, David (University of Toronto), recipient country : CA, recipient province : nan, recipient city : Ontario, recipient postal code : nan, program name english : Engage Grants for universities, program name french : Subventions d'engagement partenarial pour les universités, program purpose english : Many pharmaceuticals are complex, natural compounds that can be difficult to extract from their sources or to_x000D_
synthesize chemically. To overcome this, some pharmaceuticals can be produced in a host organism that is_x000D_
easier to manage on a commercial scale. Hyasynth Bio has developed strains of yeast that produce_x000D_
cannabinoids, a class of compounds with great potential as medicines and therapeutics. Early approved_x000D_
cannabinoid medicines in Canada include nabiximols, for adjunctive analgesic treatment in adult patients with_x000D_
advanced cancer, and nabilone, for severe nausea and vomiting associated with cancer chemotherapy. To_x000D_
rapidly screen yeast strains with improved cannabinoid production, a simple way of detecting and quantifying_x000D_
these compounds is required. We aim to develop a new means of detecting medicinal cannabinoids to improve_x000D_
their commercial production., program purpose french : Many pharmaceuticals are complex, natural compounds that can be difficult to extract from their sources or to_x000D_
synthesize chemically. To overcome this, some pharmaceuticals can be produced in a host organism that is_x000D_
easier to manage on a commercial scale. Hyasynth Bio has developed strains of yeast that produce_x000D_
cannabinoids, a class of compounds with great potential as medicines and therapeutics. Early approved_x000D_
cannabinoid medicines in Canada include nabiximols, for adjunctive analgesic treatment in adult patients with_x000D_
advanced cancer, and nabilone, for severe nausea and vomiting associated with cancer chemotherapy. To_x000D_
rapidly screen yeast strains with improved cannabinoid production, a simple way of detecting and quantifying_x000D_
these compounds is required. We aim to develop a new means of detecting medicinal cannabinoids to improve_x000D_
their commercial production., agreement title english : Chemical biosensors for improving drug production, agreement title french : Chemical biosensors for improving drug production, agreement number : EGP, agreement value : 25000.0, agreement start date : 2018-01-10, agreement end date : nan, description english : nan, description french : nan, expected results english : nan, expected results french : nan, additional information english : Grant or Award spanning more than one fiscal year (2017-2018 to 2018-2019)., additional information french : Subvention ou bourse octroyée s'appliquant à plus d'un exercice financier (2017-2018 à 2018-2019)., owner organization : nserc-crsng, owner organization title : Natural Sciences and Engineering Research Council of Canada | Conseil de recherches en sciences naturelles et en génie du Canada